Categories AlphaGraphs, Earnings, Finance
Northern Trust beats Q4 estimates with 15% earnings growth
Northern Trust Corporation (NTRS) surpassed market expectations on both revenue and earnings for the fourth quarter of 2018. The stock was down 0.23% in morning hours on Wednesday.
Total revenue, on a fully taxable equivalent (FTE) basis, grew 5% year-over-year to $1.51 billion, helped by increases in trust, investment and other service fees, other noninterest income and net interest income.
Net income grew 15% to $409.9 million and EPS grew 19% to $1.80 compared to the prior-year period.
Total assets under custody/administration dropped 6% to $10.1 trillion while total assets under management decreased 8% to $1.1 trillion.
Total consolidated trust, investment and other servicing fees grew 3% to $933.9 million in the quarter. Total C&IS trust, investment and other servicing fees remained flat versus the previous year. Custody and fund administration fees grew mainly due to new business while investment management fees and securities lending fees fell due to outflows and lower loan volumes and spreads.
Also see: Northern Trust Q4 2018 Earnings Conference Call Transcript
Total wealth management fees rose 6% year-over-year, helped by increases across all divisions, driven by new business and favorable markets.
Total other noninterest income grew 14% versus the prior-year quarter helped by increases in foreign exchange trading income and other operating income. Net interest income, on an FTE basis, grew 9% mainly due to a higher net interest margin. Total noninterest expense grew 2% year-over-year.
During the quarter, Northern Trust declared cash dividends of $5.9 million for preferred stockholders and $123.6 million for common stockholders. The company also repurchased shares worth $234.6 million in the period.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on